Redmile Group LLC Sells 659,868 Shares of AC Immune SA (NASDAQ:ACIU)

Redmile Group LLC reduced its holdings in shares of AC Immune SA (NASDAQ:ACIU) by 38.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,034,299 shares of the company’s stock after selling 659,868 shares during the quarter. Redmile Group LLC’s holdings in AC Immune were worth $2,793,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of AC Immune by 9.9% during the 4th quarter. Geode Capital Management LLC now owns 64,090 shares of the company’s stock worth $173,000 after buying an additional 5,794 shares during the period. RPO LLC bought a new position in AC Immune during the 4th quarter worth $51,000. Renaissance Technologies LLC lifted its holdings in shares of AC Immune by 14.6% during the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock worth $1,999,000 after buying an additional 94,191 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new stake in shares of AC Immune during the fourth quarter worth $27,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of AC Immune by 130.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after acquiring an additional 74,358 shares during the period. Institutional investors own 51.36% of the company’s stock.

Analysts Set New Price Targets

ACIU has been the subject of several analyst reports. HC Wainwright dropped their price objective on shares of AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. StockNews.com upgraded AC Immune from a “hold” rating to a “buy” rating in a research note on Tuesday.

AC Immune Stock Performance

Shares of NASDAQ ACIU opened at $1.53 on Thursday. The stock has a market capitalization of $153.63 million, a P/E ratio of -3.33 and a beta of 1.62. The stock’s fifty day moving average is $1.78 and its 200 day moving average is $2.49. AC Immune SA has a 52 week low of $1.43 and a 52 week high of $4.98.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.99 million. Equities research analysts forecast that AC Immune SA will post -0.62 earnings per share for the current year.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.